Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Yahoo Finance senior health reporter Anjalee Khemlani explains the process and the range of other drugs on this new list from pharmaceutical giants Pfizer (PFE), AstraZeneca (AZN), Merck (MRK ...

This report covers recent health news, including Robert F. Kennedy Jr.'s legal fees from Merck litigations, rejections of a ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.